STTK Shattuck Labs Inc.

19.63
+0.35  (+2%)
Previous Close 19.28
Open 19.1
52 Week Low 17.15
52 Week High 59.5699
Market Cap $826,870,132
Shares 42,122,778
Float 22,794,659
Enterprise Value $524,178,271
Volume 71,353
Av. Daily Volume 176,682
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
SL-279252
Solid Tumors or Lymphomas
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
SL-172154
Ovarian Cancer
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
SL-172154
Head and Neck or Skin Squamous Cell Carcinoma
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. AUSTIN, TX and DURHAM, NC, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present four posters at SITC's 36th Annual Meeting being held Wednesday, November 10, 2021 to Sunday, November 14, 2021.

    Presentation Details

    Abstract Title: Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint SL-172154 (SIRPα-Fc-CD40L) in Subjects with Platinum-resistant Ovarian Cancer
    Abstract Number: 429
    Presenter: Nehal J. Lakhani, MD, PhD, START Midwest
    Date: November 12th - 14th
    Virtual Poster…

    AUSTIN, TX and DURHAM, NC, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present four posters at SITC's 36th Annual Meeting being held Wednesday, November 10, 2021 to Sunday, November 14, 2021.

    Presentation Details

    Abstract Title: Phase 1 Dose Escalation Study of the Agonist Redirected Checkpoint SL-172154 (SIRPα-Fc-CD40L) in Subjects with Platinum-resistant Ovarian Cancer

    Abstract Number: 429

    Presenter: Nehal J. Lakhani, MD, PhD, START Midwest

    Date: November 12th - 14th

    Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

    Abstract Title: Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint (ARC) Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects with Advanced Solid Tumors or Lymphomas

    Abstract Number: 494

    Presenter: Melissa Johnson, MD, Sarah Cannon Research Institute

    Date: November 12th - 14th

    Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

    Abstract Title: Development of an Integrated Method to Quantify Receptor Occupancy for Agonist Immunotherapeutics That Stimulate Target Cells to Migrate from the Peripheral Blood

    Abstract Number: 3

    Presenter: Louis Gonzalez, PhD, Shattuck's Director of Translational Research

    Date: November 12th - 14th

    Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

    Abstract Title: LIGHT (TNFSF14) Co-stimulation Enhances Myeloid Cell Activation and Anti-tumor Immunity in the Setting of PD-1 and TIGIT Checkpoint Blockade  

    Abstract Number: 585

    Presenter: George Fromm, PhD, Shattuck's Vice President of Research & Development

    Date: November 12th - 14th

    Virtual Poster Viewing Session: 7:00 a.m. to 5:00 p.m. ET

    Further information about the Society for Immunotherapy of Cancer Meeting can be found at:

    https://www.sitcancer.org/2021/home

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com 



    Primary Logo

    View Full Article Hide Full Article
  2. AUSTIN, TX and DURHAM, NC, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in three virtual investor conferences in September 2021.  

    Presentation Details

    Conference: Citi 16th Annual BioPharma Virtual Conference
    Format: Panel Discussion, "Framing the Tip of the Spear for Novel Antibodies and Protein Therapeutics"
    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
    Date: September 9, 2021
    Time: 1:25 p.m. EST

    Conference: H.C. Wainwright…

    AUSTIN, TX and DURHAM, NC, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in three virtual investor conferences in September 2021.  

    Presentation Details

    Conference: Citi 16th Annual BioPharma Virtual Conference

    Format: Panel Discussion, "Framing the Tip of the Spear for Novel Antibodies and Protein Therapeutics"

    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer

    Date: September 9, 2021

    Time: 1:25 p.m. EST

    Conference: H.C. Wainwright 23rd Annual Global Investment Conference

    Format: Corporate Presentation

    Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer

    Date: September 13, 2021

    Time: 7:00 a.m. EST

    Conference: Morgan Stanley 19th Annual Global Healthcare Conference

    Format: Fireside Chat

    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, M.B.A., Shattuck's Chief Financial Officer

    Date: September 15, 2021

    Time: 11:45 a.m. EST

    A live webcast of the panel discussion, corporate presentation, and fireside chat will be available on the Events & Presentations section of the Company's website. A replay of the webcasts will be archived for up to 90 days following the presentation date.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com

     



    Primary Logo

    View Full Article Hide Full Article
  3. – Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2021 –

    – Reported initial safety data from SL-172154 (SIRPα-Fc-CD40L) Phase 1 trial in ovarian cancer suggesting an encouraging early safety profile and ability to dose escalate beyond prior CD40 agonist antibodies –

    – Announced plans to study SL-172154 in hematologic malignancies, Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS), with an IND filing anticipated in the fourth quarter of 2021 –

    – Reported plans to continue dose escalating in the SL-279252 (PD1-Fc-OX40L)

    – Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2021 –

    – Reported initial safety data from SL-172154 (SIRPα-Fc-CD40L) Phase 1 trial in ovarian cancer suggesting an encouraging early safety profile and ability to dose escalate beyond prior CD40 agonist antibodies –

    – Announced plans to study SL-172154 in hematologic malignancies, Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS), with an IND filing anticipated in the fourth quarter of 2021 –

    – Reported plans to continue dose escalating in the SL-279252 (PD1-Fc-OX40L) Phase 1 trial in advanced solid tumors based on trends in immune response data –

    AUSTIN, TX and DURHAM, NC, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the second quarter ended June 30, 2021 and provided recent business highlights.

    "Over the past quarter we have begun to compare and contrast the immunological effects of CD40 and OX40 stimulation in cancer patients treated with SL-172154 and SL-279252. We believe the emerging data validate the hypothesis that the ARC platform can uniquely activate the TNF superfamily and indicate that the effects of OX40 stimulation are far more subtle than innate immune stimulation of CD40. We are excited to share this data in just a few months' time at the SITC Annual Meeting," said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. "Discharging the perceived safety risks associated with dose-escalating a CD40 agonist has enabled us to broaden our clinical development strategy, including an expected IND application for expansion into both Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome in the fourth quarter of this year."

    Second Quarter 2021 Recent Business Highlights and Other Recent Developments

    ARC Clinical-Stage Pipeline

    • Continued Enrollment of SL-172154 Phase 1 Clinical Trial in Ovarian Cancer with Encouraging Safety Profile: The phase 1 trial is an open label, multi-center, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamic effects of SL-172154 administered intravenously in patients with platinum resistant ovarian cancer. SL-172154 is a dual CD47/SIRPα inhibitor and CD40 agonist. Today, Shattuck reported continued enrollment at the fourth dose level, 3.0 mg/kg, and plans to advance to the next dose level, 10.0 mg/kg. To date, no evidence of anemia, thrombocytopenia, cytokine release syndrome or liver dysfunction, nor other dose-limiting toxicities have been observed. Prior CD40 agonist antibodies have encountered dose limiting toxicities at doses of greater than 0.3 mg/kg. Initial dose-escalation data from the trial have been submitted for presentation at the SITC Annual Meeting, to be held in November 2021.
    • Anticipated IND Application for SL-172154 in AML and HR-MDS: Shattuck plans to submit to the U.S. Food and Drug Administration an investigational new drug application for a phase 1A/B clinical trial for SL-172154 in patients with AML and HR-MDS, anticipated in the fourth quarter of 2021. The trial will evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamic effects of SL-172154, as both monotherapy and in combination. In AML, Shattuck plans to evaluate SL-172154 in combination with both azacitidine and venetoclax. In both HR-MDS and TP53 mutant AML, Shattuck plans to evaluate SL-172154 in combination with azacitidine.
    • Continued Enrollment of SL-172154 Phase 1 Clinical Trial in Squamous Cell Carcinoma of the Head and Neck or Skin: Shattuck continues to enroll patients in a Phase 1 clinical trial for SL-172154, administered intratumorally, in patients with squamous cell carcinoma of the head and neck or skin. The Phase 1 trial will evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamic effects of SL-172154 as monotherapy. Initial dose-escalation data from the trial are expected in the first half of 2022.
    • Additional Dose Escalation Cohorts Added to the SL-279252 Phase 1 Clinical Trial: An analysis of data collected across a dose range of 0.0001 through 6.0 mg/kg, on two dosing schedules, demonstrated dose dependent OX40 receptor engagement of OX40 expressing T cells, and a primary pharmacodynamic effect showing rapid egress of these target cells from circulation. This effect has not been reported for prior OX40 agonist antibodies. No dose-limiting toxicities have been observed to date. Based on these data Shattuck plans to enroll additional patients at dose levels of 12.0 and 24.0 mg/kg. Because very few of the patients treated to date are known to express PD-L1 within the tumor, Shattuck plans to enroll patients with known PD-L1 positive tumors in the additional dose level cohorts. The Phase 1 trial is an open label, multi-center, dose escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamic effects of SL-279252 as monotherapy in patients with advanced solid tumors. SL-279252 is currently being developed in collaboration with Takeda Pharmaceuticals. An abstract containing data from the dose-escalation cohorts through 6.0 mg/kg has been submitted to the SITC Annual Meeting, to be held in November 2021.

    Corporate

    • Appointed Chief Technical Officer: In June 2021, Abhinav A. Shukla was appointed Chief Technical Officer. Prior to joining Shattuck, Dr. Shukla was the Chief Technical Operations Officer at Redpin Therapeutics and was responsible for all aspects of process, analytical and formulation development, and cGMP manufacturing. Previously he held several senior leadership positions, including Vice President of Manufacturing at CRISPR Therapeutics, Vice President and Head of Biologics Process Development at Shire, and Senior Vice President of Process Development and Manufacturing at KBI Biopharma. Shukla received his doctorate in Chemical and Biochemical Engineering from Rensselaer Polytechnic Institute and his undergraduate degree from the Indian Institute of Technology, Delhi.

    Second Quarter 2021 Financial Results

    • Cash Position: As of June 30, 2021, cash and cash equivalents and short-term investments were $304.8 million, as compared to $335.4 million as of December 31, 2020.
    • Collaboration Revenue: Revenue for the second quarter ended June 30, 2021 was $(4.2) million, as compared to $3.2 million for the second quarter ended June 30, 2020. The negative revenue was driven by increased expected costs required to complete the performance obligation contained in the Collaboration Agreement with Takeda as a result of changes to the SL-279252 clinical development plan.
    • Research and Development (R&D) Expenses: R&D expenses for the second quarter ended June 30, 2021 were $14.9 million, as compared to $7.8 million for the second quarter ended June 30, 2020. The increase was primarily driven by increases in clinical development, manufacturing, personnel-related costs, and laboratory capabilities.
    • General and Administrative (G&A) Expenses: G&A expenses for the second quarter ended June 30, 2021, were $5.4 million, as compared to $1.7 million for the second quarter ended June 30, 2020. The increase was primarily driven by an increase in personnel related costs to support the operational expansion and costs associated with being a public company.
    • Net Loss: Net loss was $23.6 million for the second quarter ended June 30, 2021, or $0.56 per basic and diluted share, as compared to a net loss of $6.2 million for the second quarter ended June 30, 2020, or $0.81 per basic and diluted share.

    2021 Financial Guidance

    Shattuck believes its cash and cash equivalents and short-term investments will be sufficient to fund its operations through 2024, which is beyond results from its Phase 1 clinical trials of SL-172154 and SL-279252. This cash runway guidance is based on the Company's current operational plans and excludes any additional funding that may be received or business development or additional clinical development activities that may be undertaken.

    About SL-172154

    SL-172154 is an investigational bi-functional fusion protein designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway. SL-172154 is currently being evaluated in Phase 1 clinical trials for the treatment of patients with ovarian and head and neck or skin squamous cell carcinoma.

    In preclinical studies, SL-172154, demonstrated evidence of bridging the innate and adaptive immunity, antigen cross-priming to CD8+ T cells, and durable receptor occupancy, leading to superior anti-tumor activity over anti-CD47 antibodies, and anti-CD40 antibodies, both alone or in combination. Additionally, SL-172154 preclinically demonstrated a favorable safety profile with no evidence of hematologic toxicities observed with other CD47 inhibitors.

    About SL-279252

    SL-279252 is an investigational bi-functional fusion protein designed to block the PD-1 immune checkpoint and simultaneously agonize the OX40 pathway. SL-279252 is currently being evaluated in a Phase 1 clinical trial for the treatment of patients with advanced solid tumors and lymphoma. SL-279252 is part of a collaboration with Takeda Pharmaceuticals.

    In preclinical studies, SL-279252, demonstrated evidence of high monotherapy activity, potent stimulation of OX40+ T Cells and superior anti-tumor activity over Anti-PD1/L-1 antibodies and Anti-OX40 antibodies, both alone or in combination.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Forward-Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, our expectations regarding plans for our preclinical studies, clinical trials and research and development programs, the initiation of any dose-expansion cohorts, the anticipated timing of the results from those studies and trials, the anticipated timing for IND filings, anticipated timing for preclinical development updates, the potential for our proprietary ARC technology and GADLEN platform, the clinical benefit of TIGIT blocking antibodies and T cell engagers, additional uses for our proprietary ARC technology and GADLEN platform, potential new uses for our product candidates, and expectations regarding the time period over which our capital resources will be sufficient to fund our anticipated operations. Words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While we believe these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in our filings with the U.S. Securities and Exchange Commission (the "SEC")), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: the recent and ongoing COVID-19 pandemic and associated public health guidance measures; expectations regarding the initiation, progress, and expected results of our preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of our Phase 1 clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in our Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent periodic and current reports filed with the SEC. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

    The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.Ascher@sternir.com

    SHATTUCK LABS, INC.

    BALANCE SHEETS 

    (In thousands)

     June 30, 2021December 31, 

    2020
     (unaudited)
    Assets  
    Current assets:  
    Cash and cash equivalents$86,494  $157,898  
    Short-term investments218,304  177,551  
    Prepaid expenses and other current assets11,080  10,190  
    Total current assets315,878  345,639  
    Property and equipment, net7,571  3,000  
    Other assets331  349  
    Total assets$323,780  $348,988  
       
    Liabilities and Stockholders' Equity  
    Current liabilities:  
    Accounts payable$1,007  $1,754  
    Accrued expenses11,326  7,352  
    Deferred revenue2,778  7,728  
    Total current liabilities15,111  16,834  
    Deferred revenue, net of current portion29,215  21,306  
    Deferred rent2,367  987  
    Total liabilities46,693  39,127  
    Stockholders' equity:  
    Common stock5  5  
    Additional paid-in capital386,206  382,012  
    Accumulated other comprehensive loss(1,620) (63) 
    Accumulated deficit(107,504) (72,093) 
    Total stockholders' equity277,087  309,861  
    Total liabilities and stockholders' equity$323,780  $348,988  

    SHATTUCK LABS, INC.

    STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (Unaudited) 

    (In thousands, except share and per share amounts)

     Three Months Ended June 30, Six Months Ended June 30,
     2021

      2020 2021 2020
    Collaboration revenue - related party$(4,231)  $3,181   $(1,961)  $6,157  
    Operating expenses:                   
    Research and development 14,882   7,755   25,219   15,892  
    General and administrative 5,399   1,746   9,755   3,346  
    Expense from operations 20,281   9,501   34,974   19,238  
    Loss from operations (24,512)  (6,320)  (36,935)  (13,081) 
                        
    Other income (expense):                   
    Interest income 1,000   138   1,696   387  
    Other (86)  (26)  (172)  (68) 
    Total other income 914   112   1,524   319  
    Net loss$(23,598)  $(6,208)  $(35,411)  $(12,762) 
    Unrealized loss on short-term investments (960)  (97)  (1,557)  (36) 
    Comprehensive loss$(24,558)  $(6,305)  $(36,968)  $(12,798) 
            
    Net loss per share – basic and diluted$(0.56)  $(0.81)  $(0.85)  $(1.67) 
    Weighted-average shares outstanding – basic and diluted 41,906,268   7,646,149   41,840,555   7,633,565  



    Primary Logo

    View Full Article Hide Full Article
  4. AUSTIN, TX and DURHAM, NC, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the BTIG Biotechnology Conference being held virtually August 9-10, 2021.

    Presentation Details
    Conference: BTIG Biotechnology Conference
    Format: Fireside Chat
    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer, Lini Pandite, MBChB, M.B.A, Shattuck's Chief Medical Officer, and Andrew Neill, M.B.A, Shattuck's Chief Financial Officer
    Date: August 10, 2021
    Time: 1:30 p.m. EST

    The…

    AUSTIN, TX and DURHAM, NC, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the BTIG Biotechnology Conference being held virtually August 9-10, 2021.

    Presentation Details

    Conference: BTIG Biotechnology Conference

    Format: Fireside Chat

    Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer, Lini Pandite, MBChB, M.B.A, Shattuck's Chief Medical Officer, and Andrew Neill, M.B.A, Shattuck's Chief Financial Officer

    Date: August 10, 2021

    Time: 1:30 p.m. EST

    The live webcast will be available on BTIG's conference website at the time of the event, and a replay will be available through BTIG's research access.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.ascher@sternir.com 



    Primary Logo

    View Full Article Hide Full Article
  5. AUSTIN, TX and DURHAM, NC, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2021 on Wednesday, August 11, 2021, at 4:30 p.m. ET.

    The live call may be accessed by dialing (833) 614-1555 (domestic) or (516) 575-8754 (international) and entering the conference code: 7172288. The live and archived webcast will be available on the Events & Presentations section of the Company's website. A replay of the webcast…

    AUSTIN, TX and DURHAM, NC, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2021 on Wednesday, August 11, 2021, at 4:30 p.m. ET.

    The live call may be accessed by dialing (833) 614-1555 (domestic) or (516) 575-8754 (international) and entering the conference code: 7172288. The live and archived webcast will be available on the Events & Presentations section of the Company's website. A replay of the webcast will be archived for up to 90 days following the presentation date.

    About Shattuck Labs, Inc.

    Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

    The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

    Investor Contact:

    Conor Richardson

    Senior Director, Finance & Investor Relations

    Shattuck Labs, Inc.

    InvestorRelations@shattucklabs.com

    Media Contact:

    Stephanie Ascher

    Managing Director

    Stern Investor Relations, Inc.

    Stephanie.Ascher@sternir.com



    Primary Logo

    View Full Article Hide Full Article
View All Shattuck Labs Inc. News